Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A403QV | ISIN: FR001400OLP5 | Ticker-Symbol: 6XB3
München
06.06.25 | 08:17
0,132 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOPHYTIS SA Chart 1 Jahr
5-Tage-Chart
BIOPHYTIS SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,1340,13517:25

Aktuelle News zur BIOPHYTIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
BIOPHYTIS Aktie jetzt für 0€ handeln
MiBIOPHYTIS: Biophytis announces its participation in the BIO International Convention from June 16 to 194
MoBiophytis SA - 6-K, Report of foreign issuer4
30.05.BIOPHYTIS: Information on the Annual Financial Statements5
15.05.Biophytis SA - 6-K, Report of foreign issuer3
15.05.BIOPHYTIS: Biophytis Highlights Innovative Approach to Obesity Treatment During Key ECO 2025 Presentation4
29.04.Biophytis SA - 6-K, Report of foreign issuer4
25.04.BIOPHYTIS: Postponement of the publication of the annual financial statements12
22.04.Biophytis SA - 6-K, Report of foreign issuer1
22.04.BIOPHYTIS: Biophytis targets mobility restoration in patients with obesity1
22.04.Biophytis Targets Mobility Restoration in Patients with Obesity229Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - April 22, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in developing...
► Artikel lesen
09.04.Biophytis SA - 6-K, Report of foreign issuer2
09.04.BIOPHYTIS: Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity2
09.04.Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity336Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - April 9, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the...
► Artikel lesen
31.03.Biophytis SA - 6-K, Report of foreign issuer3
28.03.BIOPHYTIS: Biophytis announces the settlement and delivery of its €2.6 million private placement4
26.03.BIOPHYTIS: Biophytis announces the successful completion of a €2,6 million private placement5
24.03.BIOPHYTIS: Biophytis announces new non-clinical data further supporting its mission to pioneer the restoration of mobility in patients with obesity3
24.03.Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity26096% of patients with obesity report experiencing muscle strength impairment, affecting their mobilityNew preclinical study results: The combination of BIO101 and GLP-1 induced muscle strength and mobility...
► Artikel lesen
20.03.Biophytis SA - 6-K, Report of foreign issuer3
17.03.BIOPHYTIS: Biophytis revolutionizes sarcopenia3
Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1